Differences in the use of tigecycline between ICU patients and non-ICU patients;Diferencias en el uso de tigeeielina entre paeientes críticos y no críticos

Revista Espanola de Quimioterapia

Volumn 23, Issue 2, 2010, Pages 63-71

  Alvarez Lerma F ^a   Blanco, L ^a   Rodriguez J A ^a   Grau, S ^a   Conde Estevez D ^a   Luque, S ^a  

^a HOSPITAL DEL MAR   (Spain)

Author keywords

Critically ill patient; Efficacy; ICU; Tigecycline; Tolerability

Indexed keywords

TIGECYCLINE;

ARTICLE; BACTERIAL FLORA; DRUG TOLERABILITY; HOSPITAL ADMISSION; HOSPITALIZATION; HUMAN; INFECTION; INTENSIVE CARE UNIT; MORTALITY; PSEUDOMONAS AERUGINOSA; TREATMENT RESPONSE;

ADULT; AGED; ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; COHORT STUDIES; DRUG UTILIZATION; FEMALE; HOSPITAL MORTALITY; HUMANS; INTENSIVE CARE; INTENSIVE CARE UNITS; MALE; MIDDLE AGED; MINOCYCLINE; RETROSPECTIVE STUDIES;

EID: 77956487342     PISSN: 02143429     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Frampton JE, Curran MP. Tigecycline. Drugs 2005; 65:2623-35.
2. Zhanel GG, Homenuik K, Nichol K, Noreddin A, Vercaigne L, Embil J, et al. The glycylcyclines: a comparative review with the tetracyclines. Drugs 2004; 64:63-88
3. Wyeth Pharmaceuticals Inc. TygacilTM (tigecycline) for injection prescribing information (on line). Available from URL: (Accessed 2008 june 2)
4. Hoban DJ, Bouchillon SK, Johnson BM, Johnson JL, Dowzicky MJ. In vitro activity of tigecycline against 6792 Gram-negative and Gram-positive clinical isolates from the global Tigecycline Evaluation Surveillance Trial (TEST Program 2004). Diagn Microbiol Infect Dis 2005; 52:215-227
5. Sader HS, Jones RN, Stilwell MG, Dowzicky MJ, Fritsche TR. Tigecycline activity tested against 26,474 bloodstream infection isolates: a collection from 6 continents. Diagn Microbiol Infect Dis 2005; 52:181-186
6. Bouchillon SK, Hoban DJ, Johnson BM, Stevens TM, Dowzicky MJ, Wu DH, et al. In vitro evaluation of tigecycline and comparative agents in 3049 clinical isolates: 2001 to 2002. Diagn Microbiol Infect Dis. 2005; 51(4):291-5.
7. Bouchillon SK, Stevens T, Johson B. Global in vitro antibacterial activity of tigecicline against methicillin resistant and methicillin sensitive Staphylococcus aureus isolates from the Tigecycline Evaluation Surveillance Trial (TEST) program. Clin Microbiol Infect 2005; 11 (suppl 2):238
8. Low DE, Kreiswirth BN, Weiss K, Willey BM. Activity of GAR-936 and other antimicrobial agents against North Americam isolates of Staphylococus aureus. Int J Antimicrob Agents 2002; 20:220-222
9. Postier RG, Green SL, Klein SR, Ellis-Grosse EJ, Loh E; Tigecycline 200 Study Group. Results of a multicenter, randomized, openlabel efficacy and safety study of two doses of tigecycline for complicated skin and skin-structure infection in hospitalized patients. Clin Ther 2004; 26:704-714
10. Sacchidanand S, Penn RL, Embil JM, Campos ME, Curcio D, Ellis-Grosse E, et al. Efficacy and safety of tigecycline monotherapy compared with vancomycin plus aztreonam in patients with complicated skin and skin structure infections: Results from a phase 3, randomized, double-blind trial. Int J Infect Dis 2005; 9:251-161
11. Breedt J, Teras J, Gardovskis J, Maritz FJ, Vaasna T, Ross DP, et al. Safety and efficacy of tigecycline in treatment of skin and skin structure infections: Results of a double-blind phase 3 comparison study with vancomycin-aztreonam. Antimicrob Agents Chemother 2005; 49:4658-66
12. Fomin P, Beuran M, Gradauskas A, Barauskas G, Datsenko A, Dartois N, et al. Tigecycline is efficacious in the treatment of complicated intra-abdominal infections. Int J Surg 2005; 3:35-47
13. Oliva ME, Rekha A, Yellin A, Maritz FJ, Vaasna T, Ross DP, et al. A multicenter trial of the efficacy and safety of tigecyclin versus imipenem/cilastatin in patients with complicated intra-abdominal infections. BMC Infectious Diseases 2005; 5:88
14. Babinchak T, Ellis-Grosse E, Dartois N, Rose GM, Loh E; Tigecycline 301 Study Group; Tigecycline 306 Study Group et al. The efficacy and safety of tigecycline for the treatment of complicated intra-abdominal infections : analysis of pooled clinical trial data. Clin Infect Dis 2005; 41 (Suppl 5):S354-67
15. Vasilev K, Reshedko G, Orasan R, Sanchez M, Teras J, Babinchak T, et al. A phase 3, open-label, non-comparative study of tygecycline in the treatment of patients with selected serious infections due to resistant Gramnegative organisms including Enterobacter species, Acinetobacter baumannii and Klebsiella pneumoniae. J Antimicrob Chemother 2008; 62 (Suppl 1):29-40
16. Florescu I, Beuran M, Dimov R, Razbadauskas A, Bochan M, Fichev G, et al. Efficacy and safety of tigecycline compared with vancomycin or linezolid for treatment of serious infections with methicillin-resistant Staphylococcus aureus or vancomycin-resistant enterococci: a Phase 3, multicentre, double-blind, randomized study. J Antimicrob Chemother 2008; 62 Suppl 1:i17-28
17. Sanchez M, Manso M, Catalán M, Blanco ML, Munoz A, Ubeda A, et al. Tratamiento de infecciones graves con tigeciclina (TGC). Estudio retrospectivo observacional, multicéntrico. Enferm Infecc Microbiol Clin 2008; 26 (Extraordinario 4); 182 (Abstract 456)
18. Swoboda S, Ober M, Hainer C, Lichtenstern C, Seiler C, Wendt C et al. Tigecicline for the treatment of patients with severe sepsis or septic shock: a drug use evaluation in a surgical intensive care unit. J Antimicrob Chemother 2008; 61:729-33
19. Le Gall JR, Lemeshow S, Saulnier F. A new simplified acute physiology score (SAPS II) based on a European/North American multicenter study. JAMA 1994; 270:2957-63
20. Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981; 30:239-45 (Pubitemid 12149145)
21. Chemaly RF, Hanmod SS, Jiang Y, Rathod DB, Mulanovich V, Adachi JA, et al. Tigecycline use in cancer patients with serious infections: a report on 110 cases from a single institution. Medicine (Baltimore). 2009;88:211-20.
22. Schafer JJ, Goll D, Stevenson KB, Mangino JE. Early experience with tigecycline for ventilator-associated pneumonia and bacteremia caused by multidrug-resistant Acinetobacter baumannii. Pharmacotherapy 2007; 27:980-7
23. Sanchez M, Manso M, Catalán M, Blanco ML, Muñoz A, Ubeda A, et al. Tratamiento de infecciones graves con tigeciclina (TGC). Estudio retrospectivo observacional, multicéntrico. Enferm Infecc Microbiol Clin 2008; 26 (Extraordinario 4); 182 (Abstract 456)
24. Alvarez Lerma F, Grau S. Tratamiento de rescate en las infecciones graves de los pacientes hospitalizados. Rev Esp Quimioterap 2007; 20:234-40
25. Papadomichelakis E, Kontopidou F, Antoniadou A, Poulakou G, Koratzanis E, Kopterides P, Mayrou I, et al. Screening for resistant gram-negative microorganisms to guide empiric therapy of subsequent infection. Intensive Care Med 2008; 34:2169-75.
26. León C, Ruiz-Santana S, Saavedra P, Almirante B, Nolla-Salas J, Alvarez-Lerma F, et al. A bedside scoring system ("Candida score") for early antifungal treatment in nonneutropenic critically ill patients with Candida colonization. Crit Care Med 2006; 34:730-737
27. Rodríguez-Baño J, Alcalá JC, Cisneros JM, Grill F, Oliver A, Horcajada JP, et al. Community infections caused by extendedspewctrum beta-lactamase producing Escherichia coli. Arch Intern Med 2008; 168:1897-902
28. Martinez JA, Aguilar J, Almela M, Marco F, Soriano A, Lopez F et al. Prior use of carbapenems may be a significant risk factor for extended-spectrum (3-lactamase-producing Escherichia coli or Klebsiella spp in patients with bacteraemia. J Antimicrob Chemother 2006; 58:1082-5
29. Wilcox MH. Evidence for low risk of Clostridium difficile infection associated with tigecycline. Clin Microbiol Infect 2007b; 13:949-52
30. Nseir S, Di Pompeo C, Brisson H, Dewavrin F, Tissier S, Diarra M et al. Intensive care unit-acquired Stenotrophomonas maltophilia: incidence, risk factors, and outcome. Crit Care 2006; 10 (5): R143